Catalio Capital Management as of Sept. 30, 2025
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 38 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 8.1 | $44M | 57k | 763.00 | |
| Abbvie (ABBV) | 6.6 | $36M | 155k | 231.54 | |
| Bridgebio Pharma (BBIO) | 6.0 | $32M | 623k | 51.94 | |
| Intuitive Surgical Com New (ISRG) | 5.9 | $32M | 71k | 447.23 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 5.3 | $29M | 145k | 198.81 | |
| Soleno Therapeutics (SLNO) | 5.2 | $28M | 418k | 67.60 | |
| Dianthus Therapeutics (DNTH) | 4.9 | $26M | 668k | 39.35 | |
| Boston Scientific Corporation (BSX) | 4.7 | $26M | 263k | 97.63 | |
| Syndax Pharmaceuticals (SNDX) | 4.6 | $25M | 1.6M | 15.38 | |
| Cytokinetics Com New (CYTK) | 4.6 | $25M | 452k | 54.96 | |
| Natera (NTRA) | 4.4 | $24M | 148k | 160.97 | |
| Regeneron Pharmaceuticals (REGN) | 3.7 | $20M | 35k | 562.27 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 3.4 | $18M | 652k | 28.00 | |
| Uniqure Nv SHS (QURE) | 3.1 | $17M | 283k | 58.37 | |
| Disc Medicine (IRON) | 2.6 | $14M | 217k | 66.08 | |
| Abivax Sa Sponsored Ads (ABVX) | 2.5 | $14M | 162k | 84.90 | |
| Supernus Pharmaceuticals (SUPN) | 2.5 | $14M | 287k | 47.79 | |
| EXACT Sciences Corporation (EXAS) | 2.5 | $14M | 249k | 54.71 | |
| Phathom Pharmaceuticals (PHAT) | 2.5 | $13M | 1.1M | 11.77 | |
| Adaptive Biotechnologies Cor (ADPT) | 2.4 | $13M | 885k | 14.96 | |
| Avidity Biosciences Ord (RNA) | 2.1 | $12M | 263k | 43.57 | |
| Adma Biologics (ADMA) | 1.9 | $10M | 685k | 14.66 | |
| Ultragenyx Pharmaceutical (RARE) | 1.6 | $8.8M | 291k | 30.08 | |
| Fractyl Health (GUTS) | 1.5 | $8.3M | 5.2M | 1.59 | |
| Grail (GRAL) | 1.5 | $8.2M | 138k | 59.13 | |
| Protara Therapeutics Com Stk (TARA) | 1.2 | $6.5M | 1.5M | 4.35 | |
| Septerna (SEPN) | 1.0 | $5.5M | 294k | 18.81 | |
| Cidara Therapeutics Com New (CDTX) | 0.9 | $5.1M | 53k | 95.76 | |
| Kyverna Therapeutics (KYTX) | 0.7 | $3.5M | 587k | 6.00 | |
| Eledon Pharmaceuticals (ELDN) | 0.5 | $2.7M | 1.1M | 2.59 | |
| Outset Med Com New (OM) | 0.3 | $1.7M | 118k | 14.12 | |
| Metagenomi (MGX) | 0.2 | $1.3M | 529k | 2.37 | |
| Atai Life Sciences Nv SHS | 0.2 | $1.0M | 197k | 5.29 | |
| Hyperfine Com Cl A (HYPR) | 0.2 | $993k | 685k | 1.45 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.2 | $955k | 133k | 7.17 | |
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $935k | 143k | 6.54 | |
| Palvella Therapeutics Inc Ne (PVLA) | 0.1 | $753k | 12k | 62.69 | |
| Sensei Biotherapeutics Com New (SNSE) | 0.0 | $139k | 15k | 9.45 |
